Articles tagged with Vascular Endothelial Growth Factor
Researchers investigated whether genetic variation in an immune system component called the complement system may contribute to vision loss during anti-VEGF therapy in wet AMD patients. Genetic variations were found to lead to complement system dysregulation, which was enhanced by blocking VEGF signaling.
A Penn-coordinated study confirms that half of patients with age-related macular degeneration retain 20/40 vision or better after five years of treatment with Avastin or Lucentis. The study also found signs of modestly worsening disease, but overall, the therapy has shown significant benefits in slowing vision loss.
Researchers at UEA discovered that reducing growth factor availability can impede cell invasion and improve the effectiveness of open-bag cataract surgery. Anti-VEGF treatment is being explored as a potential new approach to prevent secondary cataract.
Researchers found that genetically modified cord blood cells carrying VEGF and GDNF transgenes can promote tissue sparing, axonal regeneration, and motor function recovery in rats with spinal cord injuries. The study suggests these cells may be a promising strategy for enhancing posttraumatic spinal cord regeneration.
Two studies from Massachusetts General Hospital suggest that targeting both VEGF and Ang-2 pathways can normalize tumor blood vessels and shift immune cells towards an anti-tumor state. This approach has shown promise in slowing glioblastoma growth and improving survival rates.
A new study suggests that poor sleep, like sleep apnea, can promote cancer development by stimulating the formation of blood vessels in tumors. Researchers found that intermittent hypoxia, a common consequence of sleep apnea, increases vascular progenitor cells and endothelial cells within tumors.
Researchers developed a mouse model to study the effects of abnormal vascular endothelial growth factor (VEGF) levels on lung development. The study found that reduced VEGF signaling can 'turn on' lung disease, even in full-term animals, and replicate key features of neonatal respiratory distress syndrome.
A new treatment using vascular endothelial growth factor fused to a bioengineered carrier promotes the recovery of kidney function in pigs with chronic renovascular disease. The study shows that this treatment can improve kidney function, potentially leading to substantial implications for the management of renovascular disease.
Researchers discovered how a mutant protein triggers nerve damage in CMT subtype CMT2D, a group of currently untreatable conditions. The study suggests future therapies may target this haywire protein to restore nerve function in patients with CMT.
A research team at Beth Israel Deaconess Medical Center has identified a small molecule that prevents the overgrowth of blood vessels in animal models of aged macular degeneration and retinopathy of prematurity. The new findings show that this molecule, named Vasotide, can be delivered in eye drops, offering a promising alternative to ...
Researchers successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes into laboratory mice with oxygen-induced retinopathy, demonstrating the potential of MSCs to suppress causes of diabetic retinopathy and macular degeneration. The study found that AMSCs secrete growth factors that inhibit angiog...
Research finds high blood levels of vascular endothelial growth factor (VEGF) correlate with smaller prefrontal cortex and brain abnormalities in schizophrenia. This may lead to development of easier diagnostic tests and better disease understanding.
A new class of treatments may be effective in preserving vision for people with diabetic macular edema (DME). Researchers found that high levels of plasma kallikrein and associated molecules contribute to DME, and targeting this pathway may lead to new therapies.
Researchers found that neurons produce a chemical critical for blood vessel survival, which also supports photoreceptors. The study suggests a new way to understand and treat diseases like diabetic retinopathy and age-related macular degeneration.
Researchers discover that blocking Slit2 protein prevents pathological blood vessel development in the retina, leading to a potential new treatment for vasoproliferative ocular diseases. The study suggests that therapies targeting Slit2 and its receptors may be beneficial for patients resistant to conventional anti-VEGF therapies.
Researchers found that polyphenols in green tea and apples inhibit VEGF signaling, a key driver of blood vessel formation. This mechanism could help prevent chronic conditions like heart disease and cancer.
Researchers found that fruit flies can remember and crave sweeter, energy-rich foods. A growth factor controlling brain vessel formation also stimulates mouse and human neural stem cells to produce new brain cells.
Researchers have discovered that growth factor VEGF-B can regenerate damaged peripheral nerves in the cornea without inducing angiogenesis. This finding suggests that VEGF-B may be a suitable candidate to treat nerve damage in areas where blood vessel formation would be detrimental.
Researchers have found that vascular endothelial growth factor (VEGF) can stimulate soluble sFlt1 production in the placenta, contributing to the development of preeclampsia. Elevated VEGF levels during early pregnancy can cause severe placental damage and embryonic lethality.
A mouse model study suggests that elevated VEGF and sFLT1 levels during pregnancy can lead to preeclampsia-like symptoms and pregnancy loss. The findings highlight the potential consequences of therapies targeting these proteins for treating preeclampsia.
Scientists at The University of Nottingham have made a major medical discovery that could lead to the development of an entirely new type of painkiller for chronic pain conditions like traumatic nerve injury. They found that a signal protein called VEGF promotes pain while its inhibiting form prevents it.
The Champalimaud Award recognizes the development of Anti-Angiogenic Therapy for Retinal Disease, which has improved vision in patients with devastating blindness diseases. The treatment targets age-related macular degeneration and diabetic retinopathy, conditions affecting millions worldwide.
Ferrara's discovery of vascular endothelial growth factor (VEGF) led to the development of ranibizumab, a monoclonal antibody drug treating wet macular degeneration and diabetic eye disease. This achievement has significantly improved vision for patients affected by these conditions.
Researchers found that ischemic preconditioning reduced infarct volume and increased vascular endothelial growth factor (VEGF) immunoreactivity in rats. The study suggests a potential neuroprotective effect of ischemic preconditioning in focal cerebral infarction, associated with VEGF upregulation.
Research by Dr. Hyung-Seok Kim reveals that early expressions of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor increase the neuronal plasticity of activated endogenous NSCs after focal cerebral ischemia. Additionally, neural precursor cells can be recruited from nearby areas to promote neurofunctional recovery.
Researchers found that intravenous injections of dental pulp stem cells have a protective effect against brain damage from heat stroke in mice. The treatment inhibited neurological deficits and reduced oxidative damage to the brain. However, further studies are needed to determine the precise mechanism of SHED-mediated growth factors.
VEGF inhibitors cause hypertension in nearly all patients, and a subset develops severe hypertension. The mechanisms behind this effect need to be better understood for clear guidelines to be developed. Management of VEGF inhibitor-induced hypertension is crucial to reduce short-term morbidity while maintaining effective cancer treatment.
A study found that patients with high levels of vascular endothelial growth factor (VEGF) in their blood had poor response to treatment with immunotherapy ipilimumab. Combining immunotherapy with VEGF inhibitors may be a potential option for these patients.
Researchers found that aerobic fitness and hormones, including BDNF, predict recognition memory in healthy young adults. High levels of BDNF at high fitness predicted improved memory accuracy.
Researchers at Scripps Research Institute have developed a promising technique for treating human eye disease by targeting microRNAs, which can stop abnormal blood vessel growth. The approach shows promise in preventing blindness in diseases like neovascular macular degeneration and diabetic retinopathy.
Stanford researchers have identified a molecular pathway involved in diabetes development and found an approved cancer drug that can regulate it. The drug, aflibercept, works by blocking the growth of blood vessels into tumors and starving them of oxygen, which has beneficial effects on blood glucose levels.
Researchers developed a therapeutic principle using Poxue Huayu and Tianjing Busui Decoction to break blood stasis and replenish essence. The treatment demonstrated significant reductions in brain water content, intracerebral hematoma volume, and neurologic impairment in cerebral hemorrhage rat models.
The study found that Braintone increased the expression of hypoxia-inducible factor 1α, heme oxygenase-1 and vascular endothelial growth factor in ischemic cortex of rats with middle cerebral artery occlusion. This suggests a neuroprotective effect on ischemia-induced brain damage.
Researchers at the University of Wisconsin-Madison have made an engineered stem cell advance that points toward a treatment for ALS. The study, published in Molecular Therapy, found that using adult stem cells to deliver growth factors improved survival and delayed disease progression in rat models with symptoms resembling ALS.
Researchers have found that vascular endothelial growth factor (VEGF) induces the production of transforming growth factor-beta 1 (TGF-B1), which promotes fibrosis in glaucoma surgery. The study suggests that inhibiting VEGF may reduce scar formation and improve surgical outcomes.
Researchers discovered that VEGF-driven artery formation requires the binding of VEGFR2 and NRP1. Mice lacking a part of NRP1 molecule had poorly constructed arteries and failed to repair blood vessel blockages. This study opens new therapeutic opportunities for cardiovascular and anti-cancer therapies.
Researchers found that blocking VEGF-A can decrease intraocular pressure but impair the ciliary body's function. This raises concerns about the long-term effects of aggressive anti-VEGF therapies on eye diseases like wet macular degeneration and diabetic macular edema.
Researchers have decoded the entire pathway regulating blood vessel leakiness, a condition linked to disorders like heart disease and cancer. Several agents already being tested for other conditions may reverse vessel leakiness, offering new directions for clinical treatment.
Scientists at Scripps Research Institute found that drastically reducing VEGF activity in the retina can cause severe vision loss. Deleting the VEGF gene from adult mice revealed its crucial function in maintaining retinal health. Further studies are necessary to determine the effects of anti-VEGF drugs on patients.
Scientists at Stanford University School of Medicine found that neural stem cells secrete substances that activate microglia, boosting their numbers and strength. This new understanding could improve brain function and lead to the development of therapies for neurodegenerative diseases.
Researchers have identified a compound that could prevent damage to the retina in diabetic retinopathy by targeting two important pathways: inflammation and blood vessel weakening. The finding is promising for developing a new therapy.
Researchers discovered that bevacizumab can lead to invasive tumors in brain cancer patients, but found a new treatment strategy by targeting both VEGF and MET. This approach may improve survival rates for drug-resistant patients, offering hope for a more effective treatment.
A novel gene therapy strategy using hyperbranched poly(amidoamine) nanoparticles has been developed for cardiac repair. The strategy, known as HRE-VEGF, provides a safer alternative to current VEGF gene delivery systems and shows promise for treating myocardial infarction.
A type of herpesvirus infection of the eye has been found to be associated with neovascular age-related macular degeneration (AMD), a leading cause of blindness in the elderly. The virus triggers the production of vascular endothelial growth factor, leading to retinal tissue destruction and vision loss.
Age-related macular degeneration is a progressive chronic disease causing vision loss worldwide. New treatments like Lucentis and Avastin have transformed management of the condition.
The study reveals that defective Notch signalling enables strong and deregulated vessel growth even when VEGF or VEGFR2 are inhibited. A different VEGF family receptor, VEGFR3, is strongly upregulated, promoting angiogenesis.
Researchers successfully deliver genes for PDGF-BB and VEGF to mice, restoring blood flow and repairing damaged tissue without toxic effects. The balanced delivery of these factors shows promise for treating atherosclerotic disease and preventing limb amputations.
A study published in the Journal of Experimental Medicine found that persistent protein expression may explain why brain tumors return after therapy. The research suggests blocking an active VEGF receptor could represent a new treatment option for glioblastoma cases where traditional therapies have failed.
A study published in the American Journal of Ophthalmology reveals a significant reduction in new cases of legal blindness in Denmark, with the rate of blindness from AMD falling by over 50% between 2000 and 2010. The introduction of new treatment for wet AMD has been credited with this progress.
Researchers at Linköping University have identified a new target for treating psoriasis: the psoriasin protein, which stimulates cell division and angiogenesis. By inhibiting psoriasin, they believe they can reduce disease severity and minimize side effects.
A phase 2 study shows that aflibercept reduces the development of malignant ascites, a common complication of advanced ovarian cancer, and improves symptoms. However, it also increases the risk of fatal bowel perforations.
Researchers have found a blood test that can predict how well a depressed patient responds to antidepressants, such as escitalopram. The test measures vascular endothelial growth factor (VEGF) levels, with higher VEGF levels associated with greater relief from depression.
Researchers have discovered a molecular pathway that can help reduce cardiac damage caused by an enlarged heart, a common result of hypertension or a heart attack. The pathway, activated by stretch of adult cardiac cells, promotes the release of VEGF, which protects cardiac function and keeps cells alive.
A study suggests targeting ALK-1 with PF-03446962 may help patients whose cancer does not respond to existing antiangiogenic therapies. The agent showed partial responses and stable disease in seven out of 44 patients, including those with lung, renal or liver cancer.
Researchers at Weill Cornell Medical College uncover biochemical signals that trigger generation of new lung alveoli in mice. The study identifies molecular triggers behind this process, which may be relevant to humans and potentially lead to treatment for chronic obstructive pulmonary disease (COPD).
Research reveals VEGF's crucial role in regulating skin cancer stem cells, which are key to sustaining tumor growth. The study also identifies Neuropilin 1 as a critical receptor in this process, highlighting new targets for cancer therapy.
A protein that promotes neuron growth and blood vessel formation appears to halt brain degeneration in a genetic disease, according to Northwestern University research published in Nature Medicine. The study suggests a link between aging and the development of spinocerebellar ataxia type 1, a disease causing cerebellum degeneration.
Researchers found that boosting VEGF levels improves muscle coordination and balance in mice with SCA1. The study suggests a potentially useful treatment for the fatal disease, which affects 1-2 people per 100,000 population.
Research suggests exercise can stimulate the expression of two proteins thought to play a role in blood vessel health, reducing the risk of preeclampsia. Higher levels of VEGF and heat shock proteins were found in rats that exercised before and during pregnancy.
Researchers discovered a chromatin insulator binding factor CTCF that blocks VEGF activation, regulating angiogenesis and cancer progression. This finding opens a window to manage angiogenesis and cancer using CTCF as a target.